HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James D Marks Selected Research

Single-Chain Antibodies

1/2012Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
7/2010Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
2/2008Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
10/2007Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
8/2007Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
7/2007Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.
3/2006Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
1/2004Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James D Marks Research Topics

Disease

43Neoplasms (Cancer)
10/2020 - 04/2002
20Botulism
10/2021 - 12/2007
8Breast Neoplasms (Breast Cancer)
01/2018 - 09/2004
6Prostatic Neoplasms (Prostate Cancer)
10/2014 - 01/2004
5Respiratory Insufficiency (Respiratory Failure)
01/2021 - 01/2009
4Chronic Obstructive Pulmonary Disease (COPD)
08/2015 - 07/2011
3Adenocarcinoma
10/2014 - 11/2008
2Urinary Bladder Neoplasms (Bladder Cancer)
10/2020 - 10/2014
2Leukemia
11/2015 - 07/2010
2Paralysis (Palsy)
08/2015 - 01/2015
2Acquired Immunodeficiency Syndrome (AIDS)
08/2015 - 07/2010
2Neoplasm Metastasis (Metastasis)
08/2010 - 07/2007
2Infections
01/2009 - 12/2006
2Carcinoma (Carcinomatosis)
01/2005 - 06/2003
1Autoimmune Diseases (Autoimmune Disease)
10/2019
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2014
1Carcinogenesis
11/2014
1Melanoma (Melanoma, Malignant)
10/2014
1Colorectal Neoplasms (Colorectal Cancer)
10/2014
1Airway Remodeling
06/2014
1Osteosarcoma (Osteogenic Sarcoma)
01/2012
1Fibrosis (Cirrhosis)
07/2011
1Inflammation (Inflammations)
07/2011
1HIV Infections (HIV Infection)
07/2010
1Myeloid Leukemia (Leukemia, Myelocytic)
07/2010
1Lymphoma (Lymphomas)
07/2010
1Immune System Diseases (Immune Disorders)
01/2009
1Persistent Infection
01/2009

Drug/Important Bio-Agent (IBA)

20AntibodiesIBA
10/2019 - 08/2002
15Botulinum Toxins (Botulinum Toxin)IBA
10/2021 - 02/2008
14AntigensIBA
01/2018 - 10/2002
12Monoclonal AntibodiesIBA
01/2021 - 04/2002
10Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2004
9AntitoxinsIBA
01/2021 - 08/2010
8Single-Chain AntibodiesIBA
01/2012 - 01/2004
8Liposomes (Liposome)IBA
10/2006 - 04/2002
6Immunoglobulin FragmentsIBA
11/2014 - 02/2005
6Pharmaceutical PreparationsIBA
01/2009 - 04/2002
5ErbB Receptors (EGF Receptor)IBA
01/2014 - 06/2003
4incobotulinumtoxinAFDA Link
01/2021 - 12/2007
4EpitopesIBA
08/2015 - 01/2004
4Cell Surface ReceptorsIBA
10/2012 - 01/2010
4Doxorubicin (Adriamycin)FDA LinkGeneric
01/2012 - 08/2002
3AerosolsIBA
01/2021 - 01/2019
3IntegrinsIBA
10/2018 - 07/2011
3LigandsIBA
08/2015 - 08/2004
3Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA
10/2014 - 01/2012
3Trastuzumab (Herceptin)FDA Link
01/2014 - 03/2011
3Surface Antigens (Surface Antigen)IBA
01/2012 - 01/2004
2ChemokinesIBA
10/2018 - 07/2011
2Peptide Hydrolases (Proteases)FDA Link
08/2015 - 02/2010
2Immunoglobulins (Immunoglobulin)IBA
10/2014 - 10/2007
2DisulfidesIBA
06/2013 - 03/2006
2Cytotoxins (Cytolysins)IBA
01/2012 - 07/2007
2Peptides (Polypeptides)IBA
01/2012 - 03/2006
2Radioisotopes (Radionuclides)IBA
03/2011 - 02/2008
2Neoplasm Antigens (Tumor Antigens)IBA
11/2010 - 05/2009
2Biomarkers (Surrogate Marker)IBA
02/2010 - 11/2008
2Topotecan (Hycamtin)FDA LinkGeneric
01/2010 - 10/2007
2Hormones (Hormone)IBA
05/2009 - 10/2007
1GemcitabineFDA Link
10/2020
1ProdrugsIBA
10/2020
1Docetaxel (Taxotere)FDA Link
10/2020
1Type II Tumor Necrosis Factor ReceptorsIBA
10/2019
1Phenobarbital (Luminal)FDA Link
01/2018
1SmokeIBA
08/2015
1Acetylcholine (Acetylcholine Chloride)FDA Link
01/2015
1ZincIBA
01/2015
1SNARE Proteins (SNAREs)IBA
01/2015
1EndopeptidasesIBA
01/2015
1Neurotransmitter Agents (Neurotransmitter)IBA
01/2015
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
11/2014
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
10/2014
1Cell Adhesion MoleculesIBA
10/2014
1Transforming Growth Factors (Transforming Growth Factor)IBA
06/2014
1tyrosine receptor (receptor, tyrosine)IBA
01/2014
1Phosphotransferases (Kinase)IBA
01/2014
1NeurotoxinsIBA
06/2013
1Recombinant ProteinsIBA
10/2012
1Cysteine (L-Cysteine)FDA Link
06/2012
1Immunotoxins (Immunotoxin)IBA
01/2012
1Immunoconjugates (Immunoconjugate)IBA
01/2012
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
08/2010
1Transferrin Receptors (Transferrin Receptor)IBA
07/2010
1IronIBA
07/2010
1Serine (L-Serine)FDA Link
02/2010
1matriptaseIBA
02/2010
1EnzymesIBA
02/2010
1FurinIBA
12/2009
1Vincristine (Oncovin)FDA LinkGeneric
09/2009
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
05/2009
1Biological ProductsIBA
01/2009
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2008

Therapy/Procedure

14Therapeutics
07/2012 - 08/2002
5Critical Care (Surgical Intensive Care)
01/2021 - 01/2009
2Immunotherapy
10/2019 - 07/2010
1Drug Therapy (Chemotherapy)
01/2019
1Patient Transfer (Patient Dumping)
08/2015
1Anesthesia
08/2015
1Intravenous Injections
03/2011